Gilead GS-US-342-1139" A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 FDC for 12 Wks with Sofos and RBV for 12 Wks in Subjects with Chronic Genotype 2 HCV Infection